Levetiracetam
Product manufactured by Tagi Pharma, Inc.
Indications and Purposes
| 1 Indications And Usage Levetiracetam Is Indicated For Adjunctive Therapy, As An Alternative When Oral Administration Is Temporarily Not Feasible, In The Treatment Of: Partial Onset Seizures In Patients 1 Month Of Age And Older With Epilepsy ( 1.1 ) Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy ( 1.2 ) Primary Generalized Tonic-Clonic Seizures In Patients 6 Years Of Age And Older With Idiopathic Generalized Epilepsy ( 1.3 ) 1.1 Partial Onset Seizures Levetiracetam Is Indicated As Adjunctive Therapy In The Treatment Of Partial Onset Seizures In Adults And Children 1 Month Of Age And Older With Epilepsy. Levetiracetam Injection Is For Intravenous Use Only As An Alternative For Patients When Oral Administration Is Temporarily Not Feasible. 1.2 Myoclonic Seizures In Patients With Juvenile Myoclonic Epilepsy Levetiracetam Is Indicated As Adjunctive Therapy In The Treatment Of Myoclonic Seizures In Adults And Adolescents 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy. Levetiracetam Injection Is For Intravenous Use Only As An Alternative For Patients When Oral Administration Is Temporarily Not Feasible. 1.3 Primary Generalized Tonic-Clonic Seizures Levetiracetam Is Indicated As Adjunctive Therapy In The Treatment Of Primary Generalized Tonic-Clonic Seizures In Adults And Children 6 Years Of Age And Older With Idiopathic Generalized Epilepsy. Levetiracetam Injection Is For Intravenous Use Only As An Alternative For Patients When Oral Administration Is Temporarily Not Feasible. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Levetiracetam |
|
ZINC1547851 |